Chemistry:SRT1460
From HandWiki
Short description: Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C26H29N5O4S |
| Molar mass | 507.61 g·mol−1 |
| 3D model (JSmol) | |
| |
SRT1460 is a drug in development by Sirtris Pharmaceuticals intended as a small-molecule activator of the sirtuin subtype SIRT1. It has similar activity in animal studies to the known SIRT1 activator resveratrol, but is closer in potency to SRT1720. In animal studies it was found to improve insulin sensitivity and lower plasma glucose levels in fat, muscle and liver tissue, and increased mitochondrial and metabolic function.[1] However, the claim that SRT1460 is a SIRT1 activator has been questioned[2] and further defended.[3]
See also
References
- ↑ "Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes". Nature 450 (7170): 712–6. November 2007. doi:10.1038/nature06261. PMID 18046409. Bibcode: 2007Natur.450..712M.
- ↑ "SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1". The Journal of Biological Chemistry 285 (11): 8340–51. March 2010. doi:10.1074/jbc.M109.088682. PMID 20061378.
- ↑ "SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator". The Journal of Biological Chemistry 285 (43): 32695–703. October 2010. doi:10.1074/jbc.M110.133892. PMID 20702418.
 |
